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Objectives To examine the effectiveness of tocilizumab
(TCZ) with and without synthetic disease-modifying
antirheumatic drugs (sDMARDs) in a large observational
study.
Methods Patients with rheumatoid arthritis treated
with TCZ who had a baseline visit and information on
concomitant sDMARDs were included. According to
baseline data, patients were considered as taking TCZ as
monotherapy or combination with sDMARDs. Main study
outcomes were the change of Clinical Disease Activity
Index (CDAI) and TCZ retention. The prescription of TCZ
as monotherapy was analysed using logistic regression.
CDAI change was analysed with a mixed-effects model
for longitudinal data. TCZ retention was analysed with a
stratiﬁed extended Cox model.
Results Multiple-adjusted analysis suggests that
prescription of TCZ as monotherapy varied according to
age, corticosteroid use, country of the registry and year
of treatment initiation. The change of disease activity
assessed by CDAI as well as the likelihood to be in
remission were not signiﬁcantly different whether TCZ
was used as monotherapy or in combination with
sDMARDs in a covariate-adjusted analysis. Estimates for
unadjusted median TCZ retention were 2.3 years
(95% CI 1.8 to 2.7) for monotherapy and 3.7 years
(lower 95% CI limit 3.1, upper limit not estimable) for
combination therapies. In a covariate-adjusted analysis,
TCZ retention was also reduced when used as
monotherapy, with an increasing difference between
mono and combination therapy over time after 1.5 years
(p=0.002).
Conclusions TCZ with or without concomitant
sDMARDs resulted in comparable clinical response as
assessed by CDAI change, but TCZ retention was shorter
under monotherapy of TCZ.
INTRODUCTION
Biological disease-modifying antirheumatic drugs
(bDMARDs) have markedly changed the manage-
ment and outcome of rheumatoid arthritis (RA).
Tocilizumab (TCZ), a monoclonal anti-interleukin-6
receptor antibody, has proven to be efﬁcacious in
patients who did not respond to methotrexate
(MTX) or other synthetic DMARDs (sDMARDs),
as well as after failure to respond to tumour necro-
sis factor (TNF) antagonists, and to prevent the pro-
gression of structural damage.1–3 These ﬁndings
have led to the inclusion of TCZ in the algorithm
of RA management as a ﬁrst-line bDMARD after
MTX failure similar to TNF antagonists or
abatacept.4
Most international guidelines recommend the
use of bDMARDs in combination with MTX or
other sDMARDs in case MTX is not tolerated or
contraindicated.4 These recommendations are pri-
marily based on the observation that MTX
enhances the efﬁcacy of TNF antagonists in both
clinical trials and observational studies.5–7 In two
randomised clinical trials including adult patients
with RA with inadequate response to MTX,
patients were randomised to receive either intraven-
ous TCZ as monotherapy or in combination with
MTX. The results of these studies showed that,
when considering some endpoints, the combination
with MTX offered some advantage over TCZ as
monotherapy. However, both strategies were asso-
ciated with meaningful clinical and radiographic
responses.8–11 To date, however, data from large,
observational, multinational studies on TCZ effect-
iveness are lacking.
The objective of this study, based on data from
several European registries, was to analyse the
characteristics of patients who were treated with
TCZ as monotherapy and the effectiveness of
TCZ, with particular attention to its use as mono-




The TOcilizumab Collaboration of European
Registries in RA is an investigator-led, industry-
supported initiative with the aim to evaluate clinical
aspects of TCZ use in patients with RA. Each regis-
try obtained ethical approval for the use of anon-
ymised data for research separately. The
data-contributing registries were ATTRA (http://
www.attra.registry.cz), Czech Republic (CS);
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DANBIO (http://www.danbio-online.dk), Denmark (DK);
ROB-FIN (http://www.reumatologinenyhdistys.ﬁ), Finland (FI);
DREAM-RA (http://www.dreamregistry.nl), the Netherlands
(NL); NOR-DMARD, Norway (NO); Reuma.pt (http://www.
reuma.pt), Portugal (PT); ARBITER, Russia (RU); BioRx.si,
Slovenia (SI); SRQ (Swedish Rheumatology Quality Register,
http://www.srq.nu), Sweden (SE); SCQM (Swiss Clinical Quality
Management in Rheumatic Diseases, http://www.scqm.ch),
Switzerland (CH). All patients included in the different registries
who had started treatment with TCZ by the end of 2013/begin-
ning of 2014 were considered eligible for the present study if
(1) the patient had a diagnosis of RA established by a rheuma-
tologist, (2) the patient had initiated TCZ treatment after the
end of 2008 at an age of 18 years or older, (3) a baseline visit
within 90 days prior to start of TCZ was available and (4) base-
line information on the use of sDMARD co-therapy were avail-
able. In the rare case of patients who have experienced several
treatment courses (TCs) with TCZ (identiﬁed by a difference of
at least 60 days between stop and restart of TCZ treatment)
after 2008 for which the above-stated inclusion criteria were
met, the earliest one was selected. Any follow-up visit for which
the available information allowed to conclude, unambiguously,
that it had occurred after the start of TCZ and before 60 days
after stop of TCZ treatment was considered valid and included.
Exposure of interest
TCZ treatments were classiﬁed as either monotherapy (‘TCZ’)
or as one of three types of combination therapy with sDMARDs
such as (1) with MTX only (‘TCZ+MTX’), (2) with MTX and
at least one other sDMARD (‘TCZ+MTXplus’) or (3) with at
least one other sDMARD (‘TCZ+other’), depending on the
presence of concomitant sDMARDs at baseline.
Study outcomes
Our main focus was on investigating the change of disease
activity following initiation of TCZ therapy in terms of Clinical
Disease Activity Index (CDAI) and TCZ retention in relation to
the type of TCZ therapy. TCZ retention was deﬁned as the
time from the start date of TCZ treatment until the TCZ dis-
continuation date. If TCZ had not been discontinued, TCZ
retention was censored at the date of the last reported
follow-up visit. For TCZ retention, only patients who had not
been lost to follow-up immediately after start of TCZ and who
were not from Russia where regular treatment with TCZ had
been discontinued for administrative reasons in a number of
patients were regarded eligible. We also used the disease activ-
ity score (DAS) 28 as a secondary outcome measure. The
DAS28 calculation for a given patient was based on either the
erythrocyte sedimentation rate (ESR) three*item formula
(28 joint counts for tender and swollen joints and the ESR in
mm/h) or the C reactive protein (CRP) three-item formula
(with CRP in mg/L), depending on the amount of available and
valid information for ESR and CRP, with a preference for the
ESR-based formula. For 60% of patients, the ESR-based
formula was used.
Covariates
The baseline covariates considered were sex, age, disease dur-
ation, number of previously used biologics, seropositivity (pres-
ence of rheumatoid factor (RF) or anticyclic citrullinated
peptide antibodies (anti-CCP)), corticosteroid use, functional
disability (Health Assessment Questionnaire (HAQ)), DAS28,
year of TCZ treatment start and country of registry. Details on
covariates are described in the online supplementary material.
Statistical methods
The prescription of TCZ as monotherapy versus in combination
with sDMARDs in relation to patient characteristics at baseline
was analysed using logistic regression analyses. CDAI and
DAS28 change over time was visualised by means of smoothing
using a local quadratic regression approach and analysed with
mixed-effects models for longitudinal data. TCZ retention was
analysed using Kaplan–Meier and Cox models, with the add-
ition of time-varying covariate effects (extended Cox models).
The frequency of disease remission (CDAI <2.8 or DAS28
<2.6) under treatment was assessed at various times post-TCZ
start. For 16–34% of patients, depending on the analysis, infor-
mation for at least one covariate was missing. We reanalysed our
main analyses (prescription of monotherapy, TCZ retention and
CDAI/DAS28 change) based on multiple imputation of missing
covariate data. Detailed information on statistical methods,
models and software is available from the online supplementary
material.
RESULTS
A total of 2057 patients fulﬁlling all the inclusion criteria and
providing a total of 13 131 follow-up visits were retrieved from
the different registries. Of the 1498 patients with available
information, all but 52 started TCZ treatment with a dose of
≥6 mg/kg. A ﬂow chart of the patients considered eligible and
included in the different analyses is shown in online supplemen-
tary figure S1.
Baseline patient characteristics associated
with TCZ prescription
TCZ was most frequently initiated in combination with MTX
(1011 TCs), followed by TCZ as monotherapy (577 TCs), TCZ
with sDMARDs other than MTX (285 TCs) and, lastly, by TCZ
in combination with MTX and other sDMARD(s) (184 TCs).
For the majority of patients (89% for TCZ, 68% for TCZ
+MTX, 61% for TCZ+MTXplus and 73% for TCZ+other),
sDMARD co-therapy did not change over time. A description
of patient characteristics by type of TCZ treatment is provided
in online supplementary table S1.
The results from a multiple-adjusted analysis of the probabil-
ity of prescribing TCZ as monotherapy suggest that (1) coun-
tries differ in their prescription attitude with respect to TCZ as
monotherapy, (2) TCZ as monotherapy has become more fre-
quent over the years, (3) it is more frequently prescribed to
older patients with RA and (4) it is more frequently prescribed
to patients without concomitant corticosteroid therapy (table 1).
Due to their effect on the prescription of monotherapy, these
four covariates must be regarded as potential confounding vari-
ables with respect to TCZ treatment.
The results from an analysis based on multiple imputation of
missing covariates were comparable to those from the reported
complete-case analysis (data not shown).
Change of disease activity
The CDAI at baseline of TCZ initiation was inﬂuenced by
country of registry, year of TCZ treatment initiation, the
number of prior biologics and sex (online supplementary table
S2). The CDAI decreased rapidly after the start of TCZ, regard-
less of whether TCZ was used as monotherapy or in combin-
ation with sDMARDs (ﬁgure 1). A virtually identical result was
observed when disease activity was assessed using DAS28
(online supplementary figure S2). A covariate-adjusted longitu-
dinal analysis of both CDAI and DAS28 provided similar results
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with respect to the effect of TCZ treatment as monotherapy or
in combination with sDMARDs. The estimated differences in
CDAI between the four treatment groups at various times based
on the longitudinal model are shown in table 2. Some covariates
had signiﬁcant effects on CDAI change, such as country of regis-
try, year of TCZ treatment initiation and number of previously
used biologics (online supplementary table S2). Similar results
were obtained for DAS28 (see online supplementary material).
An analysis based on multiple imputation of missing covariates
provided results comparable to those from the complete-case
analysis, especially with respect to the effect of type of TCZ
treatment (data not shown). Combining the different combin-
ation therapy groups into one group resulted in the same con-
clusions for CDAI and DAS28 (data not shown).
The frequency of disease remission in terms of CDAI
(CDAI<2.8), as assessed at various times after TCZ initiation,
was about 20% overall (ﬁgure 2). At 6 months, the
covariate-adjusted OR for CDAI remission in patients treated
with TCZ in combination with MTX versus TCZ as monother-
apy was 1.03 (95% CI 0.76 to 1.40). The respective OR at
12 months was 1.06 (95% CI 0.79 to 1.42). For ‘TCZ
+MTXplus’ and ‘TCZ+other’ versus ‘TCZ’, the ORs were 0.79
(95% CI 0.49 to 1.27) and 0.77 (95% CI 0.50 to 1.16) at
6 months and 0.81 (95% CI 0.52 to 1.28) and 0.81 (95% CI
0.54 to 1.21) at 12 months. Comparable data were observed for
DAS28 remission (see online supplementary material), with the
exception of an overall higher frequency of DAS28 remission in
all treatment groups.
TCZ retention
Discontinuation of TCZ therapy was observed in 700 (39%) of
the 1798 eligible patients. Main causes for discontinuation were
lack of effectiveness (mentioned for 50% of discontinued
patients for monotherapy and 52% for combination therapies)
Table 1 Summary of baseline covariates and their relation to prescription of tocilizumab (TCZ) as monotherapy
Prescription of TCZ as monotherapy
Covariate Summary (n=2057) Proportion of mono (%) OR (95% CI) for mono (n=1359)
Age (years) 55 (13.1)
56 (46–64)
1.38 (1.11 to 1.71) per 20 years more
Sex (%) (n=2056) Male 21 24 Reference
Female 79 29 1.30 (0.92 to 1.83)
Disease duration (years) (n=1900) 11.4 (9.5)
9.1 (4.1–16.1)
1.11 (0.96 to 1.27) per 10 years more
Seropositivity (%) (n=1891) No 18 27 Reference
Yes 82 28 1.08 (0.75 to 1.54)
Number of prior biologics (%)
(n=2056)
0 19 29 Reference
1 26 26 0.82 (0.54 to 1.25)
≥2 55 28 0.76 (0.51to 1.13)
Corticosteroids (%) (n=2011) No 51 33 Reference
Yes 49 22 0.74 (0.56 to 0.99)
DAS28 (n=1914) 5.0 (1.4)
5.1 (4.1–6.0)
1.14 (0.89 to 1.45) per 2 units more
HAQ (n=1673) 1.4 (0.7)
1.5 (1.0–2.0)
0.95 (0.77 to 1.19) per 1 unit more
Year of TCZ initiation (%) 2009 15 19 Reference
2010 23 22 1.23 (0.78 to 1.96)
2011 20 24 1.40 (0.87 to 2.25)
2012 22 35 2.07 (1.30 to 3.28)
2013 20 38 2.58 (1.62 to 4.10)
Country (%) Czech Republic 12.9 23 0.66 (0.39 to 1.12)
Denmark 35.5 31 0.92 (0.60 to 1.39)
Finland 2.3 11 0.36 (0.10 to 1.27)
The Netherlands 2.4 28 –
Norway 3.8 52 –
Portugal 8.4 15 0.46 (0.24 to 0.87)
Russia 4.1 11 0.30 (0.12 to 0.79)
Slovenia 9.5 21 0.28 (0.14to 0.55)
Sweden 6.4 38 1.41 (0.82 to 2.44)
Switzerland 14.7 34 Reference
Sample sizes (n) equal the number of eligible patients presented in the header of column ‘Summary’ unless indicated otherwise. The column named ‘Summary’ provides a description of
covariates in terms of mean (SD) and median (IQR) for discrete or continuous covariates and percentages for categorical covariates. The column named ‘Proportion of mono’ provides the
frequency of monotherapy-initiated TCZ treatment for each category of a categorical covariate. The last column presents estimated ORs and 95% Wald CIs for prescribing TCZ as
monotherapy (as compared to any type of combination therapy) based on multiple logistic regression. ORs for discrete or continuous covariates are presented for a difference
corresponding approximately to the IQR. For categorical covariates, ORs with respect to the chosen reference category are shown. p Values from likelihood ratio tests for categorical
covariates with more than two categories were 0.41 for number of prior biologics, <0.0001 for year of TCZ initiation and <0.0001 for country. The multiple logistic regression is based on
all TCs with complete covariate information. The Netherlands (patchy data) and Norway (no HAQ recorded) lack TCs with complete covariate information.
DAS, disease activity score; HAQ, Health Assessment Questionnaire; TC, treatment courses.
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and safety issues (mentioned for 32% of discontinued patients
for monotherapy and 28% for combination therapies). In
23 patients (5 from monotherapy and 18 from combination
therapies), TCZ was discontinued due to disease remission.
Unadjusted estimates of TCZ retention curves suggest that, at
later times, TCZ is more often discontinued when initiated as
monotherapy, as compared to when initiated in combination
therapy (all three types of combination therapy combined)
(ﬁgure 3). Respective estimates for unadjusted median retention
were 2.3 years (95% CI 1.8 to 2.7) for monotherapy and
3.7 years (lower 95% CI limit: 3.1, upper limit not estimable;
see ﬁgure 3) for combination therapies. This conjecture was sup-
ported by the ﬁnding of a time-dependent effect of TCZ treat-
ment on the hazard for TCZ discontinuation in both an
unadjusted and covariate-adjusted analysis. In both cases, we
observed an increasing difference with time after 1.5 years
(table 3). Of all other covariates, only seropositivity and HAQ
were found to signiﬁcantly affect the hazard for TCZ discon-
tinuation (online supplementary table S4). There were also
major differences in TCZ retention curves between countries
(online supplementary figure S4).
The results from the analysis based on multiple imputation of
missing covariates were comparable to those from the reported
complete-case analysis, particularly with respect to the effect of
type of TCZ treatment (data not shown).
DISCUSSION
This study included a large number of patients with RA from
different European countries treated with TCZ in either mono-
therapy or in combination with MTX or different combinations
of sDMARDs. Prescription of TCZ as monotherapy varied
according to some intrinsic patient characteristics (age and use
of corticosteroids), as well as the extrinsic factors, country of
the registry and year of treatment initiation. The change of
disease activity assessed by CDAI and DAS28, as well as the like-
lihood to be in remission, was not signiﬁcantly different
whether TCZ was used as monotherapy or in combination with
sDMARDs. However, TCZ retention was more prolonged when
TCZ was prescribed in combination with sDMARDs.
Despite current recommendations to use bDMARDs with
MTX or other sDMARDs, several reports from different coun-
tries show that in routine practice approximately 30% of
patients with RA receive bDMARDs as monotherapy. In this
study, we observed that older patients were more likely to be
treated with TCZ as monotherapy. This result is consistent with
two other observational studies that have shown that monother-
apy with bDMARDs is more often prescribed to older patients
with also longer disease duration, a higher number of previous
DMARDs and more comorbidities.7 12 Thus, it is likely that
patients treated in TCZ monotherapy represent a subgroup of
patients who are more difﬁcult to manage and exhibit intoler-
ance to MTX and other sDMARDs. Unfortunately, comorbid-
ities were not captured by most registries, thus limiting our
analysis on the inﬂuence of other medical conditions on the use
of TCZ as monotherapy. However, it is plausible that older mul-
timorbid patients could have been preferentially treated with
TCZ alone rather than in combination with MTX or other
sDMARDs.
Taking advantage of the inclusion of registries representing
different European countries, we have observed signiﬁcant dif-
ferences regarding the prescription of TCZ. Variations regarding
local treatment recommendations, as well as TCZ licensing
(in combination with MTX or sDMARDs), most likely explain
these variations. The signiﬁcant increase in the prescription of
TCZ as monotherapy over the years, and particularly after
2012, is likely explained by the results of studies demonstrating
that TCZ as monotherapy is a reasonable treatment option.8 10
Furthermore, TCZ as monotherapy was signiﬁcantly more efﬁ-
cacious than adalimumab as monotherapy in patients with RA
with inadequate response to MTX.13
Figure 1 Smoothed time courses of Clinical Disease Activity Index
(CDAI) by tocilizumab (TCZ) treatment. The data represent all 1702
eligible patients with at least one CDAI value totalling 9943
observations. Data were smoothed separately for each TCZ treatment
using local quadratic regression. Treatment groups ‘TCZ’, ‘TCZ+
methotrexate (MTX)’, ‘TCZ+MTXplus’, and ‘TCZ+other’ represent TCZ as
monotherapy and in combination with MTX, MTX+other synthetic
disease-modifying antirheumatic drugs (sDMARD(s)), and at least one
sDMARD other than MTX, respectively. Numbers of patients providing
CDAI information beyond 12, 24, 36 and 48 months were 162, 76, 32
and 7 for ‘TCZ’, 427, 262, 133 and 41 for ‘TCZ+MTX’, 80, 41, 21 and
11 for ‘TCZ+MTXplus’, and 90, 55, 27 and 11 for ‘TCZ+other’,
respectively. Of note, all Swedish patients were excluded due to lack of
a global physician’s assessment of disease in this registry.
Table 2 Estimated differences in Clinical Disease Activity Index









2 0.44 (−0.94 to 1.81) 1.54 (−0.49 to 3.57) 1.90 (−0.01 to 3.80)
6 0.30 (−0.97 to 1.57) 1.38 (−0.51 to 3.27) 1.62 (−0.14 to 3.38)
12 0.10 (−1.10 to 1.30) 1.15 (−0.64 to 2.93) 1.22 (−0.44 to 2.87)
18 −0.10 (−1.35 to 1.14) 0.91 (−0.92 to 2.74) 0.81 (−0.87 to 2.51)
24 −0.31 (−1.70 to 1.08) 0.68 (−1.34 to 2.69) 0.41 (−1.47 to 2.29)
Estimated differences and 95% Wald-type CIs for each combination treatment versus
monotherapy based on a covariate-adjusted longitudinal mixed effects analysis are
shown. A positive difference means that CDAI under monotherapy is estimated lower
than under the respective combination treatment at this time point. The p values (from
F-tests) for an effect of type of TCZ treatment were 0.16 for the initial linear decrease
over 2 months and 0.46 for the subsequent linear phase. All 1428 eligible patients with
information on CDAI and complete covariate information were included. The distribution
of patients between the four TCZ treatments was comparable to the whole population.
Overall, 281 patients lacked a baseline CDAI and 242 provided only one CDAI value (for
176 of these this was the baseline value). Of note, all Swedish patients were excluded
due to lack of a global physician’s assessment of disease in this registry. All patients
from the Netherlands were excluded due to incomplete data.
MTX, methotrexate.
Gabay C, et al. Ann Rheum Dis 2016;75:1336–1342. doi:10.1136/annrheumdis-2015-207760 1339
Clinical and epidemiological research
group.bmj.com on July 15, 2016 - Published by http://ard.bmj.com/Downloaded from 
The efﬁcacy of TCZ as monotherapy in comparison to its use
in combination with MTX or other sDMARDs in patients with
RA with inadequate response to MTX has been examined in
clinical trials. The ACT-RAY study examined the efﬁcacy and
safety of switching to TCZ monotherapy or adding TCZ to
MTX in patients with active disease despite MTX therapy. The
results after 24 weeks did not show any advantage of the com-
bination over TCZ as monotherapy.8 After 52 weeks, patients
treated with TCZ in combination with MTX had a signiﬁcantly
higher percentage of DAS28 remission, a lower erosion score
and a higher percentage of patients without radiographic pro-
gression. Of note, all other clinical endpoints did not differ
between the two treatment groups.9 After 104 weeks, the two
treatment groups were also signiﬁcantly different regarding
changes in total radiographic and erosion scores but not for clin-
ical endpoints.10 Using a similar study design, other investiga-
tors showed that ACR response rates and the percentage of
patients who achieved DAS28 remission after 52 weeks were
not signiﬁcantly different in the monotherapy group compared
with the combination group (70.3% vs 72.2%).14 Taken
together, the results of these clinical trials suggest that concomi-
tant use of MTX provides a slight advantage for some end-
points. A 24-week large open-labelled study comparing the
efﬁcacy and safety of TCZ used as monotherapy or in
Figure 2 Frequency of Clinical
Disease Activity Index (CDAI) remission
(CDAI <2.8) by tocilizumab (TCZ)
treatment. The numbers (n) shown in
the legend indicate the number of
ongoing treatment courses for which a
CDAI value was available within
±30 days of a certain post-baseline
time point. At none of the time points
was there a signiﬁcant difference
between TCZ treatment types (Fisher’s
exact tests at 5% level). Treatment
groups ‘TCZ’, ‘TCZ+ methotrexate
(MTX)’, ‘TCZ+MTXplus’ and ‘TCZ+other’
represent TCZ as monotherapy and in
combination with MTX, MTX+other
synthetic disease-modifying
antirheumatic drugs (sDMARD(s)) and
at least one sDMARD other than MTX,
respectively.
Figure 3 Kaplan–Meier plot of tocilizumab (TCZ) retention by TCZ
treatment. These unadjusted data represent all 1798 eligible patients.
Small diagonal lines indicate censored retention times (at date of last
follow-up visit), dashed lines 95% CIs for the survival curves and
numbers above the x-axis denote the numbers of patients known to be
still at risk for TCZ discontinuation (ie, still on TCZ and not yet lost to
follow-up). Treatment groups ‘TCZ’ and ‘TCZ+ synthetic
disease-modifying antirheumatic drugs (sDMARD(s))’ represent TCZ as
monotherapy and in combination with sDMARDs, respectively. For
‘TCZ+sDMARD(s)’ the upper 95% CI line does not cross the 50% line
for the probability to stay on TCZ resulting in an unestimable upper
95% CI limit for the median retention time.
Table 3 Effect of tocilizumab (TCZ) monotherapy on hazard for TCZ
discontinuation over time
HR 95% CI p Value
TCZ vs TCZ+sDMARD(s)
In first 1.5 years 1.10 0.87 to 1.39 0.41*
At 2 years 1.54 1.19 to 1.99 0.003†
At 3 years 3.00 1.62 to 5.56
At 4 years 5.86 2.07 to 16.57
Shown are estimated HRs, 95% Wald CIs and associated p values at various times
based on a country-stratified, covariate-adjusted extended Cox proportional hazards
analysis of TCZ retention.
*p Value for the effect of TCZ treatment (monotherapy vs combination therapy) in the
first 1.5 years,
†p Value for the change in the effect of TCZ treatment with time after 1.5 years. All
1198 eligible patients who had not been lost to follow-up immediately, were not from
Russia and had complete covariate information were included (number of events=464).
The distribution of patients and events between TCZ treatments was comparable to the
case with all 1798 eligible patients. Of note, all patients from Norway and the
Netherlands were excluded due to lack of complete covariate information.
sDMARD, synthetic disease-modifying antirheumatic drugs.
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combination with sDMARDs in 1681 patients with RA with
inadequate response to sDMARDs or TNF inhibitors found that
TCZ had comparable efﬁcacy and safety when used as mono-
therapy or in combination with sDMARDs.15 In an observa-
tional registry study from Japan, the odds to achieve DAS28
remission were not different in patients treated with TCZ alone
or in combination with MTX. However, there was an increased
probability for achieving remission for TCZ in combination
compared with TCZ alone in a subset of patients with high
baseline DAS28 >5.1.16
We observed that TCZ retention was shorter in patients
treated with TCZ as monotherapy compared with the groups
treated in combination with sDMARDs. Drug retention can be
inﬂuenced by many factors, including effectiveness, tolerance,
remission, costs and patients’ or physicians’ preferences. We
could not easily explain this ﬁnding by differences in effective-
ness or safety. The marked variations of treatment retention
observed between registries could be reﬂective of differences in
local licensing, treatment recommendations, economic situation
or available treatment options. Of note, the difference in TCZ
retention between mono and combination therapy of TCZ
seemed irrelevant for the ﬁrst 1.5 years and then increased over
time. It is thus possible that after an initial improvement in
disease activity patients under TCZ monotherapy start to ﬂare
sooner than patients under TCZ in combination with
sDMARDs, leading to an increased hazard for TCZ discontinu-
ation at later times. However, our data analysis did not show
such a behaviour (data not shown). Of note, after a 104-week
follow-up, the proportion of patients in the monotherapy group
who withdrew because of lack of efﬁcacy was numerically larger
than in the combination treatment group in ACT-RAY.10
Our study included a relatively large group of patients fol-
lowed longitudinally for several years, representative of different
practices in Europe. It may, however, suffer from potential lim-
itations inherent to the analysis of observational data.
Confounding by indication may result in biased estimates for
the effect of type of TCZ treatment. We counteracted this in
our covariate-adjusted analyses, but we cannot exclude the pres-
ence of residual confounding by other unmeasured confounders.
For example, apart from the number of biologics received prior
to TCZ treatment, we have not considered any other informa-
tion relating to previous treatments. Another possible confoun-
der missing from our investigations is the presence of
comorbidities. Missing data is another potential concern. We
have rerun some of our analyses based on multiple imputation
of missing covariates and obtained comparable results to our
complete-case analysis, particularly for the type of TCZ treat-
ment. We prefer the complete-case analysis over the multiple
imputation approach for several reasons. A complete-case ana-
lysis is unbeatable in its simplicity and non-error-prone imple-
mentation. Furthermore, after careful consideration of the likely
missingness mechanisms at work, we concluded that a complete-
case analysis is more likely to give unbiased results than an
analysis based on multiple imputation.17–19 Our international
collaboration was useful to increase the number of patients
treated with TCZ for our analyses. However, we observed
important heterogeneity between countries with a clear impact
on treatment habits, the prescription of TCZ, as well as in drug
retention that may lead to difﬁculty in interpreting the data.
In conclusion, we have found that age, corticosteroid use,
country of residence and year of treatment initiation inﬂuenced
prescription of TCZ as monotherapy. TCZ with or without con-
comitant sDMARDs resulted in comparable clinical response,
but TCZ retention was reduced under TCZ monotherapy.
Author afﬁliations
1Division of Rheumatology, University Hospitals of Geneva, Geneva, Switzerland
2SCQM Foundation, Zurich, Switzerland
3DANBIO, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup,
Denmark
4Department of Clinical Medicine, Faculty of Health and Medical Sciences, University
of Copenhagen, Glostrup, Denmark
5Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
6Institute of Rheumatology and Clinic of Rheumatology, Charles University Prague,
Prague, Czech Republic
7University Medical Center, Ljubljana, Slovenia
8Rheumatology Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal, on
behalf of the Rheumatic Diseases Portuguese Register (Reuma.pt)
9The Karolinska Institute, Stockholm, Sweden
10Institute of Rheumatology, Moscow, Russia
11Department of Medicine, Helsinki University Central Hospital and University of
Helsinki, Helsinki, Finland
12Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
13Cantacuzino Hosp, Bucharest, Romania
14Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain
15Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
Correction notice This article has been corrected since it was published Online
First. The spelling of the 8th author’s surname has been corrected.
Twitter Follow M. Victoria Hernández at @MD27409
Contributors All the authors have provided substantial contributions to the
conception or design of the work, the acquisition of the data and the interpretation
of data. MR performed the statistical analysis. CG and MR made the ﬁrst draft. All
the other authors participated in the ﬁnal drafting of the work or revising it critically
for important intellectual content. All authors contributed to the ﬁnal approval of
the version published. Agreement to be accountable for all aspects of the work in
ensuring that questions related to the accuracy or integrity of any part of the work
are appropriately investigated and resolved.
Funding The TOCERRA collaboration is funded by Roche.
Competing interests CG has received fees for speaking and/or consulting from
AbbVie, BMS, Roche, Pﬁzer, Celgene, MSD, Janssen Cilag, Amgen, UCB, and
received research funding from Roche, AbbVie, MSD and Pﬁzer. The SCQM
Foundation is funded by the Swiss Society of Rheumatology, and by Abbvie, BMS,
MSD, Pﬁzer, Roche, UCB and Janssen. In addition, SCQM has received project-based
ﬁnancial supports from various institutions and companies (eg, Arco Foundation,
Switzerland, or Schweizerischer Verein Balgrist, Switzerland). MR is employed by
SCQM. MLH has received fees for consulting and/or research grant from BMS, MSD,
Pﬁzer, Abbott, UCB and Roche. DANBIO is funded by hospital authorities in
Denmark and has received unrestricted grants from AbbVie, BMS, Hospira, MSD,
Pﬁzer, Roche and UCB. E-MH has received fees for speaking and/or consulting from
MSD and AbbVie; and received research funding to Aarhus University Hospital from
AbbVie and Roche. KP has received fees for speaking and/or consulting from
AbbVie, Roche, Amgen, MSD, BMS, UCB and Egis. ATTRA was partially supported
by the project from the Czech Ministry of Health for conceptual development of
research organisation 023728 (Institute of Rheumatology). MT has received fees for
speaking and/or consulting from Abbvie, Roche, MSD, and Pﬁzer paid to Revmatic
d.o.o. BioRx.si has received funding for clinical research paid to Društvo za razvoj
revmatologije from AbbVie, Roche, Medis, MSD and Pﬁzer. HC has received fees for
consulting from Roche and Pﬁzer. Reuma.pt is supported by unrestricted grants from
Abbvie, MSD, Roche and Pﬁzer. GL has received fees for consulting from BMS,
Roche, MSD, AbbVie and Pﬁzer. The ARBITER registry is supported by a
non-commercial partnership with ‘Equalrights to life’. DCN has received fees for
speaking and/or consulting from Abbvie, BMS, MSD, Roche, UCB and Pﬁzer.
ROB-FIN is funded by AbbVie, Hospira, BMS, MSD, Pﬁzer, Roche and UCB. EL has
received fees for speaking and/or consulting from AbbVie, Bristol-Myers Squibb,
Hospira, Pﬁzer, Roche and UCB. IA has received fees for speaking and/or consulting
from MSD, AbbVie, Roche, Pﬁzer, BMS and UCB. PLMCvR has received consulting
fees and research grants from AbbVie, Pﬁzer, Roche, Eli Lilly, BMS and UCB.
DREAM-RA is funded by AbbVie, Roche, Pﬁzer, UCB and BMS. RvV has received
fees for speaking and/or consulting from AbbVie, Biotest, BMS, Crescendo, GSK,
Janssen, Lilly, Merck, Pﬁzer, Roche, UCB and Vertex; and research grants from
AbbVie, BMS, GSK, Pﬁzer, Roche and UCB. TKK has received fees for speaking and/
or consulting from AbbVie, BMS, Celgene, Celltrion, Eli Lilly, Hospira, Merck-Serono,
MSD, Orion Pharma, Pﬁzer, Roche, Sandoz and UCB and received research funding
to Diakonhjemmet Hospital from AbbVie, BMS, MSD, Pﬁzer, Roche and UCB.
NOR-DMARD was previously supported with research funding to Diakonhjemmet
Hospital from AbbVie, BMS, MSD/Schering-Plough, Pﬁzer/Wyeth, Roche and UCB.
Ethics approval EC from different institutes for the collection of clinical data in
registries.
Provenance and peer review Not commissioned; externally peer reviewed.
Gabay C, et al. Ann Rheum Dis 2016;75:1336–1342. doi:10.1136/annrheumdis-2015-207760 1341
Clinical and epidemiological research
group.bmj.com on July 15, 2016 - Published by http://ard.bmj.com/Downloaded from 
Data sharing statement All the data are presented in the main manuscript and
in the online supplementary material.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
REFERENCES
1 Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor
inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION
study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:
987–97.
2 Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab
improves treatment outcomes in patients with rheumatoid arthritis refractory to
anti-tumour necrosis factor biologicals: results from a 24-week multicentre
randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516–23.
3 Fleischmann RM, Halland AM, Brzosko M, et al. Tocilizumab inhibits structural joint
damage and improves physical function in patients with rheumatoid arthritis and
inadequate responses to methotrexate: LITHE study 2-year results. J Rheumatol
2013;40:113–26.
4 Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the
management of rheumatoid arthritis with synthetic and biological disease-
modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:
492–509.
5 Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study:
a multicenter, randomized, double-blind clinical trial of combination therapy with
adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in
patients with early, aggressive rheumatoid arthritis who had not had previous
methotrexate treatment. Arthritis Rheum 2006;54:26–37.
6 Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the
combination of etanercept and methotrexate compared with each treatment alone
in patients with rheumatoid arthritis: double-blind randomised controlled trial.
Lancet 2004;363:675–81.
7 Soliman MM, Ashcroft DM, Watson KD, et al. Impact of concomitant use of
DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid
arthritis: results from the British Society for Rheumatology Biologics Register.
Ann Rheum Dis 2011;70:583–9.
8 Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to
tocilizumab monotherapy in methotrexate inadequate responders: 24-week
symptomatic and structural results of a 2-year randomised controlled strategy trial in
rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43–50.
9 Dougados M, Kissel K, Conaghan PG, et al. Clinical, radiographic and immunogenic
effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis:
the ACT-RAY study. Ann Rheum Dis 2014;73:803–9.
10 Huizinga TW, Conaghan PG, Martin-Mola E, et al. Clinical and radiographic
outcomes at 2 years and the effect of tocilizumab discontinuation following
sustained remission in the second and third year of the ACT-RAY study. Ann Rheum
Dis 2015;74:35–43.
11 Takeuchi T, Kaneko Y, Atsumi T, et al. Adding Tocilizumab or switching to
Tocilizumab monotherapy in RA patients with inadequate response to Methotrexate:
24-week results from a randomized controled study (surprise study). Ann Rheum Dis
2013;72(Suppl 3):62.
12 Gabay C, Riek M, Scherer A, et al. Effectiveness of biological DMARDs in
monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis
—data from the Swiss Clinical Quality Management Registry. Rheumatology
(Oxford) Published Online First: 27 Apr 2015.
13 Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus
adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA):
a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381:1541–50.
14 Takeuchi T, Kaneko Y, Atsumi T, et al. Clinical and radiographic effects after
52-week of adding Tocilizumab or switching to tocilizumab in RA patients with
inadequate response to methotrexate: results from a prospective randomized
controlled study (SURPRISE study). Ann Rheum Dis 2014;73(Suppl 2):686.
15 Bykerk V, Östör AJK, Alvaro-Gracia J, et al. Comparison of tocilizumab as
monotherapy or with add-on disease-modifying antirheumatic drugs in patients with
rheumatoid arthritis and inadequate responses to previous treatments: an
open-label study close to clinical practice. Clin Rheumatol 2015;34:563–71.
16 Kojima T, Yabe Y, Kaneko A, et al. Importance of methotrexate therapy concomitant
with tocilizumab treatment in achieving better clinical outcomes for rheumatoid
arthritis patients with high disease activity: an observational cohort study.
Rheumatology (Oxford) 2015;54:113–20.
17 White IR, Carlin JB. Bias and efﬁciency of multiple imputation compared
with complete-case analysis for missing covariate values. Stat Med
2010;29:2920–31.
18 Allison PD. Multiple imputation for missing data: a cautionary tale. Sociol Method
Res 2000;28:301–9.
19 Little RJA, Rubin DB. Statistical analysis with missing data. 2nd edn, Oxford: Wiley,
2002.
1342 Gabay C, et al. Ann Rheum Dis 2016;75:1336–1342. doi:10.1136/annrheumdis-2015-207760
Clinical and epidemiological research
group.bmj.com on July 15, 2016 - Published by http://ard.bmj.com/Downloaded from 
European collaborative study
drugs in rheumatoid arthritis: results from a
synthetic disease-modifying antirheumatic 
Effectiveness of tocilizumab with and without
Kvien
Hernández, Piet L M C van Riel, Ronald van Vollenhoven and Tore K 
Galina Lukina, Dan C Nordström, Elisabeth Lie, Ioan Ancuta, M Victoria
Karel Pavelka, Matija Tomsic, Helena Canhao, Katerina Chatzidionysiou, 
Cem Gabay, Myriam Riek, Merete Lund Hetland, Ellen-Margrethe Hauge,
doi: 10.1136/annrheumdis-2015-207760
September 15, 2015
2016 75: 1336-1342 originally published onlineAnn Rheum Dis 
 http://ard.bmj.com/content/75/7/1336






Supplementary material can be found at: 
References
 #BIBLhttp://ard.bmj.com/content/75/7/1336
This article cites 17 articles, 9 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (3226)Rheumatoid arthritis
 (4904)Musculoskeletal syndromes
 (5085)Immunology (including allergy)
 (692)Drugs: musculoskeletal and joint diseases
 (4597)Degenerative joint disease




To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on July 15, 2016 - Published by http://ard.bmj.com/Downloaded from 
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on July 15, 2016 - Published by http://ard.bmj.com/Downloaded from 
